Cannabis Clinical Trials

Israel’s Therapix Biosciences has entered into an exclusive agreement with Catalent Pharma Solutions of New Jersey for the formulation, development and clinical manufacturing of THX-TS01, a first-in-class, proprietary investigational drug candidate for treating symptoms of Tourette Syndrome. Catalent will develop THX-TS01 in softgel form at its development and manufacturing facility in St. Petersburg, Florida. Tourette […]

by

OTTAWA, ONTARIO–(Marketwired – Oct. 18, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR). Tetra has signed a distribution agreement with its […]

by

TEL AVIV, Israel, October 18, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (Nasdaq: TRPX) (“Therapix” or the “Company”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, signed an agreement with Assuta Medical Center, the largest hospital network and private healthcare provider in Israel, to conduct a Phase IIa, sponsor-initiated trial (the “OSA […]

by